Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Rani Therapeutics Holdings, Inc.
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| | 10-K | 8-K | 10-K | 8-K | 10-K | S-1 |
| Revenues | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | 173.3% | 0.0% | 1999.1% | 0.0% | 2864.6% |
| Gross profit | | -73.3% | 100.0% | -1899.1% | 100.0% | -2764.6% |
| Research and development | | | 974.7% | | 2606.9% | |
| General and administrative | | 73.3% | 1024.4% | 1024.4% | 1074.0% | 353.9% |
| EBITDA | | -173.3% | -1880.8% | -1899.1% | -3453.5% | -2706.9% |
| Depreciation | | | 18.3% | | 127.5% | 57.6% |
| EBIT | | -173.3% | -1899.1% | -1899.1% | -3581.0% | -2764.6% |
| Pre-tax income | | -172.8% | -1952.4% | -1952.4% | -3607.8% | -2715.7% |
| Income taxes | | 0.2% | 1.5% | 1.5% | 7.6% | 0.0% |
| Net income | | -173.0% | -306.6% | -1953.9% | 0.0% | 0.0% |
|